Portolan Capital Management, LLC Applied Genetic Technologies Corp Transaction History

Portolan Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.29 - $0.89 $1,362 - $4,180	-4,697 Reduced 0.29%	1,600,902 $435,000
Q1 2022 May 16, 2022	BUY	$1.07 - $2.71 $262,037 - $663,665	244,895 Added 18.0%	1,605,599 $1.72 Million
Q4 2021 Feb 14, 2022	BUY	$1.87 - $2.91 $181,919 - $283,093	97,283 Added 7.7%	1,360,704 $2.59 Million
Q3 2021 Nov 15, 2021	SELL	$3.01 - $4.12 $400,167 - $547,737	-132,946 Reduced 9.52%	1,263,421 $3.8 Million
Q2 2021 Aug 16, 2021	SELL	$3.62 - $5.23 $450,827 - $651,333	-124,538 Reduced 8.19%	1,396,367 $5.46 Million
Q1 2021 May 17, 2021	BUY	$3.94 - $8.19 $839,921 - $1.75 Million	213,178 Added 16.3%	1,520,905 $7.71 Million
Q4 2020 Feb 16, 2021	BUY	$3.99 - $5.7 $26,541 - $37,916	6,652 Added 0.51%	1,307,727 $5.35 Million
Q3 2020 Nov 16, 2020	BUY	$4.38 - $6.43 $2.26 Million - $3.31 Million	515,088 Added 65.53%	1,301,075 $6.32 Million
Q2 2020 Aug 14, 2020	BUY	$3.0 - $6.9 $930,573 - $2.14 Million	310,191 Added 65.19%	785,987 $4.35 Million
Q1 2020 May 14, 2020	BUY	$2.36 - $9.86 $1.12 Million - $4.69 Million	475,796 New	475,796 $1.56 Million

Ticker AGTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,632,200
Description
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Pha...

Get notified when there are updates to the investment portfolio of Portolan Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Portolan Capital Management, LLC with notifications on news.